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Many studies have identified metabolic pathways
that underlie cellular transformation, but the meta-
bolic drivers of cancer progression remain less well
understood. The Hippo transducer pathway has
been shown to confer malignant traits on breast
cancer cells. In this study, we used metabolic map-
ping platforms to identify biochemical drivers of
cellular transformation and malignant progression
driven through RAS and the Hippo pathway in breast
cancer and identified platelet-activating factor ace-
tylhydrolase 1B3 (PAFAH1B3) as a key metabolic
driver of breast cancer pathogenicity that is upregu-
lated in primary human breast tumors and correlated
with poor prognosis. Metabolomic profiling suggests
that PAFAH1B3 inactivation attenuates cancer
pathogenicity through enhancing tumor-suppress-
ing signaling lipids. Our studies provide a map of
altered metabolism that underlies breast cancer
progression and put forth PAFAH1B3 as a critical
metabolic node in breast cancer.
INTRODUCTION
Cancer cells possess fundamentally dysregulated metabolism
that underlies their pathogenic features (Benjamin et al., 2012;
Vander Heiden et al., 2009). Targeting alteredmetabolism in can-
cer cells has historically served as a validated strategy for treat-
ing cancer patients. These therapies include chemotherapeutics
such as 5-fluorouracil, methotrexate, and anastrozole that target
nucleotide, folate, and estrogen metabolism, respectively
(National Cancer Institute, 2013). More recent discoveries have
focused on targeting other aspects of dysregulated cancer
metabolism, including glycolysis, tricarboxylic acid (TCA) cycle,
and lipogenesis with pyruvate kinase M2 (PKM2) activators, iso-
citrate dehydrogenase inhibitors, and fatty acid synthase (FASN)
inhibitors, respectively (Benjamin et al., 2012; Menendez and
Lupu, 2007; Vander Heiden et al., 2009). Whereas targeting dys-
regulated metabolism is a promising strategy for cancer treat-
ment, currently available chemotherapies, including those that
target certain aspects of cancer metabolism, fail to eradicate
the most aggressive cancers (Chambers et al., 2002).Chemistry & Biology 21,Studies over the past decade have uncovered a subpopula-
tion of cancer cells termed cancer stem/precursor cells (CSCs)
that, like embryonic stem cells, can undergo a process of epithe-
lial-to-mesenchymal transition (EMT), which is associated with
self-renewing and tumor-initiating capabilities, poor prognosis,
and chemotherapy resistance within breast tumors (Polyak and
Weinberg, 2009). Recent studies have identified TAZ, a trans-
ducer of the Hippo pathway, as a critical factor that is elevated
in poorly differentiated human breast tumors, is correlated with
poor prognosis, promotes EMT, is stabilized by EMT, and is
required to sustain self-renewal and tumor-initiation capacities
of breast CSCs (Cordenonsi et al., 2011; Hong and Guan,
2012). Identifying altered metabolic pathways that underlie
both cellular transformation and malignant progression through
TAZ may thus yield therapeutic strategies for combatting malig-
nant breast cancers.
Whereas targeting dysregulated metabolism is a promising
therapeutic strategy for cancer treatment, nearly all research in
cancer metabolism has focused on well-understood metabolic
pathways in central carbon metabolism and has largely ignored
the majority of cellular metabolic pathways, despite genetic or
metabolic evidence of their involvement in cancer. This is in large
part because of our incomplete understanding of metabolic net-
works in normal physiology, let alone in dysregulated or rewired
biochemical networks in human cancer cells (Benjamin et al.,
2012).
In this study, we used proteomic, functional proteomic, and
metabolomic platforms to more broadly identify commonly
altered metabolic pathways that underlie both mammary epithe-
lial cell transformation by the oncogene HRAS as well as malig-
nant progression, EMT, and cancer-stem-cell-like features
through the constitutive activation of TAZ in the MCF10A non-
transformed mammary epithelial cell line background. Through
these profiling efforts, we have identified platelet-activating
factor acetylhydrolase 1B3 (PAFAH1B3) as a critical enzyme in
maintaining breast cancer cell aggressiveness and tumor growth
through regulating tumor-suppressing lipids.
RESULTS AND DISCUSSION
Breast Cancer Progression Model
In this study, we used integratedmetabolicmapping platforms to
identify enzymes and metabolites that are dysregulated in a
MCF10A breast cancer progression model, a series of isogeni-
cally derived human mammary cell lines consisting of nontrans-
formed MCF10A cells, HRAS-transformed MCF10A-T1k cells831–840, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 831
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Chemistry & Biology
PAFAH1B3 in Breast Cancer(premalignant, also known as MII), and fully malignant MCF10A-
CA1a (MIV) cells, derived in vivo from spontaneous progression
of MII cells (Santner et al., 2001; Figure S1 available online). With
in vivo orthotopicmodels, MII cells generate low-grade tumors in
approximately 25% of xenografts, whereas the MIV lines form
high-grade tumors, resembling grade III human breast tumors,
at a much higher frequency. This well-characterized progression
model displays many important features of breast cancer pro-
gression found in highly aggressive metaplastic and claudin-
low breast tumor subtypes including EMT, expansion of CSC
population, and the associated increase in expression of the
stem-cell-associated CD44+/CD24/low antigenic profile, self-
renewal capabilities, and resistance to conventional therapies
(Chaffer and Weinberg, 2011; Gupta et al., 2009). In particular,
Cordenonsi et al. (2011) recently reported that MIV cells show
significantly higher self-renewal ability, tumorigenic potential,
and an increased CSC population than MII cells, resembling
the difference between grade III and grade I human breast
tumors. By analyzing a large human patient data set, they iden-
tified TAZ as a key signature that is overrepresented in poorly
differentiated high-grade tumors and correlates with increased
CSCs, metastasis, and reduced survival. TAZ, a transducer of
the Hippo-signaling pathway that mediates cell-cell contact
and polarity signals to control cell proliferation and organ size
(Chan et al., 2011), is also expressed at higher levels in MIV cells
than MII cells and is required to sustain self-renewal and tumor-
initiation capacities in breast CSCs. Consistent with previous re-
ports, we show that expression of a constitutively active TAZ,
TAZ S89A, in MCF10A or MII cells results in increased EMT, col-
ony formation in soft agar, and cellular migration (Cordenonsi
et al., 2011; Figure S1).
Identifying Dysregulated Metabolic Pathways
Underlying Cellular Transformation and Malignant
Progression
Our goal was to employ multiple metabolic mapping platforms
to broadly identify dysregulated metabolic pathways that under-
lie cellular transformation and malignant progression using the
aforementioned breast cancer model. We performed shotgun
proteomic analysis, activity-based protein profiling (ABPP)
using the serine hydrolase-directed activity-based probe, and
targeted single reaction monitoring (SRM) liquid chro-
matography/mass spectrometry (LC/MS)-based metabolomicFigure 1. Identifying Dysregulated Metabolic Enzymes in Breast Canc
(A) Shotgun proteomic profiling of metabolic enzyme expression in the breast c
expression of each protein, normalized to the highest expression of each protein a
light blue corresponds to lower expression. Lower bar graphs show themetabolic
S89A, and MIV cells.
(B) ABPP of serine hydrolase activities in the breast cancer progression model b
based probe. Upper heatmap shows relative serine hydrolase activities of each p
lines. Dark blue corresponds to high activity, and white or light blue corresponds to
significantly upregulated across 10A TAZ S89A, MII, MII TAZ S89A, and MIV cel
(C) Metabolomic profiling of the breast cancer progression model using SRM
heatmap shows relative metabolite activities normalized to MCF10A control cells
Lower bar graphs show the metabolites that were significantly elevated in levels a
presented as mean ± SEM; n = 4–6/group. Significance is presented as *p < 0.05
data are shown in Table S1. Characterization of breast cancer progression mode
regulation of these metabolic enzyme targets by the Hippo pathway, and addition
shown in Figure S1.
Chemistry & Biology 21,analyses to identify commonly altered changes in protein
expression of metabolic enzymes, activities of serine hydro-
lases, and metabolite levels, respectively, that may underlie
cellular transformation and TAZ-mediated malignant progres-
sion. Whereas shotgun proteomic profiling provides broad
coverage of alterations in protein expression, ABPP uses
active-site-directed chemical probes to identify dysregulated
activities of large numbers of enzymes (Nomura et al., 2010a).
We chose to profile the serine hydrolase superfamily for this
study because this enzyme class is one of the largest metabolic
enzyme classes in the human genome with a broad range of
functions including esterase, lipase, hydrolase, deacetylase,
thioesterase, protease, and peptidase activities, and many
serine hydrolases have been shown to be important in cancer
(Long and Cravatt, 2011). Through these profiling efforts, we
identified several enzymes and lipids that were either specif-
ically upregulated by constitutive activation of TAZ or commonly
upregulated in 10A TAZ S89A, MII, MII TAZ S89A, and MIV cells
(Figures 1A–1C and S1; Table S1). The dysregulated enzymes
identified through shotgun proteomics include glycolytic en-
zymes (enolase 1 [ENO1], glyceraldehyde-3-phosphate dehy-
drogenase [GAPDH], PKM2, phosphoglycerate kinase [PGK1],
lactate dehydrogenase A [LDHA], and aldolase A [ALDOA]),
the de novo lipogenesis enzyme FASN, and the glycogen-
metabolizing enzyme glycogen phosphorylase B (PYGB)
(Figures 1A and S1; Table S1). ABPP of serine hydrolases also
revealed FASN upregulation, in addition to peptidases (dipep-
tidyl peptidase 9 [DPP9], acylpeptide hydrolase, and prolyl
endopeptidase), lipases (PAFAH1B2 and PAFAH1B3), and sialic
acid acetylesterase (SIAE) (Figure 1B; Table S1). Metabolomic
analysis yielded several metabolites that were commonly
heightened across the four cell lines, including lipids (phospha-
tidyl ethanolamine [PE], phosphatidyl serine [PS], and sphingo-
myelin [SM]), the glycolytic intermediate phosphoenolpyruvate
(PEP), nucleotides (AMP and uridine monophosphate [UMP]),
uridine-diphosphate-conjugated sugars (UDP-glucose and
UDP-glucuronic acid), the sialic acid N-acetylneuraminic acid,
the amino acid proline, and the antioxidant glutathione (Fig-
ure 1C; Table S1). Certain enzymes such as monoacylglycerol
lipase (MGLL), the serine protease fibroblast activation protein
(FAP), and protein methyl esterase 1 (PPME1) were upregulated
specifically by constitutive activation of TAZ (Figure S1;
Table S1). Antioncogenic enzymes such as succinateer Progression Model
ancer progression model by MudPIT. Upper heatmap shows relative protein
cross the five cell lines. Dark blue corresponds to high expression, and white or
enzymes that were significantly upregulated across 10A TAZS89A,MII, MII TAZ
y ABPP-MudPIT using the fluorophosphonate-biotin serine hydrolase activity-
rotein, normalized to the highest expression of each protein across the five cell
lower activity. Lower bar graphs show the serine hydrolase activities that were
ls.
-based targeted liquid chromatography-tandem mass spectrometry. Upper
. Dark blue corresponds to high levels, and white corresponds to lower levels.
cross 10A TAZ S89A, MII, MII TAZ S89A, and MIV cells. Data in bar graphs are
compared to MCF10A control cells, #p < 0.05 compared to MII cells. Detailed
l, TAZ S89A-specific changes in metabolic enzymes, additional data showing
al data showing regulation of glycolytic metabolism by RAS and TAZ S89A are
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A Figure 2. Screening for Nodal Metabolic
Enzymes in Breast Cancer
(A) We transiently knocked down the expression of
representativemetabolic enzymes in the pathways
that we identified as consistently dysregulated in
the breast cancer progressionmodel with siRNA in
MII TAZ S89A cells.
(B–D) Knockdowns were confirmed by qPCR 48 hr
after siRNA transfection. We screened for en-
zymes that, when inactivated, impaired various
aspects of cancer pathogenicity, including cellular
proliferation (B), serum-free cell survival (C), and
cell migration (D) in MII TAZ S89A cells. Cells were
transfected with siRNA for 48 hr before seeding
into phenotypic experiments. Proliferation and cell
survival were assessed 48 hr after seeding cells by
the WST1 cell viability assay. Migration was as-
sessed by counting the number of cells migrated
through Transwell chambers over 24 hr. Data in
bar graphs are presented asmean ± SEM; n = 3–5/
group normalized to siControl. Significance is
presented as *p < 0.05 compared to siControl MII
TAZ S89A control cells.
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PAFAH1B3 in Breast Cancerdehydrogenases (SDHAs) as well as several other citric acid cy-
cle enzymes were specifically downregulated upon induction
with TAZ S89A (Figure S1; Table S1).
Overall, our data indicate that cellular transformation and
malignant progression heighten glycolysis and glycogen meta-
bolism, de novo lipogenesis, nucleic acid metabolism, sialic
acid metabolism, oxidative stress, and specific branches of lipid
metabolism. Many of these pathways, including glycolytic and
glycogen metabolism, nucleic acid metabolism, sialic acid
metabolism, oxidative stress, and de novo lipogenesis, have
been previously shown to be critical pathways that underlie
cancer metabolism and pathogenicity. Nonetheless, we show
that both HRAS transformation as well as constitutive activation
of TAZ induces glycolytic, glycogen, and sialic acid metabolism
and that TAZ and HRAS act synergistically in many cases (e.g.,
ENO1, GAPDH, PKM2, LDHA, ALDOA, PGK1, PYGB, UDP-
glucose, and N-acetylneuraminic acid) to enhance these
metabolic pathways (Figure S1). Additionally, we confirmed
heightened glycolytic metabolism in these lines by measuring
glucose consumption and lactic acid secretion and found that
both are heightened upon transduction with TAZ S89A or
HRAS and further heightened upon transduction with both TAZ
S89A and HRAS. The highly malignant MIV cells also show
significantly heightened glycolytic metabolism beyond that of
MII cells (Figure S1). Interestingly, the enzymes specifically upre-
gulated by TAZ, such as MGLL, FAP, and PPME1, or downregu-
lated by TAZ, such as SDHA, have all been implicated as critical
drivers of cancer progression (Bachovchin et al., 2011; Kelly,
2005; Nomura et al., 2011; Nomura et al., 2010b; Puustinen
et al., 2009; Yang et al., 2013).
Our data indicate that many of the aforementioned metabolic
enzymes are upregulated upon induction with TAZ S89A. We
wanted to determine whether these enzymes are regulated by
TAZ in aggressive MIV cells. Upon knocking down TAZ in
MIV cells, we observed only modest reductions in the expres-
sion of the presumably TAZ-regulated targets, including PA-
FAH1B2, ENO1, ALDOA, DPP9, and NANS (Figure S1).
Because both YAP and TAZ may regulate overlapping tran-834 Chemistry & Biology 21, 831–840, July 17, 2014 ª2014 Elsevier Lscriptional targets, we proceeded to knockdown both YAP
and TAZ in MIV cells. Interestingly, YAP and TAZ dual knock-
down led to more robust reductions in the expression
of most TAZ-regulated targets, including PAFAH1B2, ENO1,
ALDOA, PGK1, LDHA, PKM2, DPP9, MGLL, and NANS (Fig-
ure S1). PAFAH1B3 was not altered, even upon TAZ and YAP
knockdown (Figure S1). We interpret this lack of change to
perhaps indicate that other oncogenic pathways, such as
HRAS, may regulate this enzyme or that PAFAH1B3 may be
regulated by posttranslational mechanisms.
Screening for Metabolic Enzymes that Are Required for
Breast Cancer Pathogenicity
We next sought to identify metabolic enzymes that, when in-
activated, would impair cancer pathogenicity. We used small
interfering RNA (siRNA) to transiently knockdown the expression
of the dysregulated metabolic enzymes that we found through
our profiling studies and identified those enzymes that impaired
cellular proliferation, survival, or motility upon siRNA inactivation
in MII TAZ S89A cells (Figures 2A–2D). To filter a large list
of dysregulated metabolic enzyme targets, we narrowed our
focus on those enzymes found by shotgun proteomics and
ABPP and enzymes that control metabolites found by meta-
bolomics that were altered across 10A TAZ S89A, MII, MII
TAZS89A, and MIV cells. Whereas inactivation of glycolytic-,
glycogen-, and sialic-acid-metabolizing enzymes modestly
impaired proliferative, survival, or migratory capacity, we were
surprised to find that knockdown of PAFAH1B2 and PAFAH1B3
caused the most significant and dramatic impairments in the
proliferative, survival, and migratory phenotypes in MII TAZ
S89A cells (Figures 2A–2D). Thus, we decided to further investi-
gate the role of PAFAH1B2 and PAFAH1B3 in breast cancer
pathogenicity.
Characterizing the Pathological Role of PAFAH1B2 and
PAFAH1B3 in Breast Cancer
Intrigued by our initial findings in our screen in the MII TAZ S89A
cells, we next wanted to ascertain whether PAFAH1B2 andtd All rights reserved
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PAFAH1B3 in Breast CancerPAFAH1B3 inactivation also impaired breast cancer pathoge-
nicity in a more realistic patient-derived breast cancer cell line.
We thus stably inactivated the expression of PAFAH1B2 and
PAFAH1B3 in the highly aggressive estrogen receptor/proges-
terone receptor/HER2 receptor-negative (i.e., triple negative)
human breast cancer cells, 231MFP, a line derived from a breast
cancer patient adenocarcinoma MDA-MB-231 that has been
in vivo passaged in mice to derive a malignant and more aggres-
sive variant (Jessani et al., 2004). Using two independent short
hairpin RNA oligonucleotides (shPAFAH1B2-1, shPAFAH1B2-
2, shPAFAH1B3-1, and shPAFAH1B3-2), PAFAH1B2 and
PAFAH1B3 were knocked down by >80% as measured by
both quantitative PCR (qPCR) and ABPP-MudPIT (Figure 3A;
Figure S2). Knockdown of PAFAH1B2 or PAFAH1B3 significantly
impaired 231MFP cell proliferation, survival, migration, and inva-
siveness in culture and slowed or eliminated in vivo tumor growth
in immune-deficient mice (Figures 3B–3F; Figure S2). Thus, our
results suggest that PAFAH1B enzymes are important in main-
taining aggressive features of cancer.
Upon profiling the gene expression of PAFAH1B2 and
PAFAH1B3 in primary breast tumors, we found that PAFAH1B3,
but not PAFAH1B2, was significantly heightened in human
breast tumors compared to normal mammary tissue (Figure 3G).
Based on the online Kaplan-Meier plotter resource for breast
cancer recurrence-free survival, PAFAH1B3 expression is corre-
lated with low recurrence-free survival in breast cancer patients
overall, in lymph-node-positive tumors, and in grade 1–3 breast
cancer patients (Figure 3H; Gyo¨rffy et al., 2010).
From our phenotypic studies, we found that PAFAH1B3
inactivation produced more striking antitumorigenic effects
compared with that of PAFAH1B2. Furthermore, PAFAH1B3
expression, but not PAFAH1B2 expression, was significantly
higher in primary human breast tumors compared to normal
tissue. Thus, we focused our attention on further investigating
the pathophysiological and metabolic roles of PAFAH1B3 in
driving breast cancer pathogenicity. Whereas we do not under-
stand the mechanistic basis for the differences in tumor growth
deficits conferred by PAFAH1B2 or PAFAH1B3 knockdown, it
will be of future interest to analyze the tumors that grow out in
shPAFAH1B2 xenograft tumors.
We next overexpressed both the catalytically active and
the inactive serine to alanine mutant form of PAFAH1B3
(Ser47Ala or S47A) in MCF10A cells to determine whether this
enzyme was sufficient to confer oncogenic properties (Fig-
ure S2). Whereas overexpression of the wild-type form of
PAFAH1B3 did not alter proliferation or survival, wild-type
PAFAH1B3, but not the catalytically inactivemutant, significantly
enhanced cell migration, indicating that PAFAH1B3 exerts at
least some of its pathogenic effects through its catalytic activity
(Figure S2). Our studies also indicate that whereas PAFAH1B3
overexpression may be not sufficient to confer heightened pro-
liferation or survival in the nontransformed MCF10A cells, its
activity is sufficient to heighten mammary epithelial cell migra-
tion. Because PAFAH1B3 has been shown to interact with
PAFAH1B2, PAFAH1B1, as well as ubiquitin ligase LNX1, it will
be of future interest to coexpress these other binding partners
to determine whether this coupled expression is sufficient to
drive other malignant features of cancer (Rual et al., 2005; Swee-
ney et al., 2000).Chemistry & Biology 21,Metabolomic Characterization of PAFAH1B3-Regulated
Pathways in Breast Cancer
The putative function of PAFAH1B3 is to act as a deacetylase for
the signaling lipid platelet-activating factor (PAF) (Hattori et al.,
1995; Manya et al., 1999). Although recombinant PAFAH1B3
can cleave PAF in vitro (Figure S3), we found that extracellular
and intracellular PAF levels are unchanged in shPAFAH1B2
and shPAFAH1B3 231MFP cells and PAFAH hydrolytic activity
was not reduced upon PAFAH1B2 and PAFAH1B3 knockdown,
indicating that PAFAH1B is not the dominant enzyme controlling
PAF levels or PAF hydrolytic activity in 231MFP cells. Thus,
PAFAH1B3 is likely not controlling cancer pathogenicity through
controlling PAF-signaling pathways (Figure S3).
We next performed targeted and untargeted LC/MS-based
metabolomic profiling to identify metabolic changes in the lip-
idome conferred by PAFAH1B3 knockdown in 231MFP breast
cancer cells (Figures 4A and 4B; Table S2). We subsequently
interpreted only those changes in lipid levels that were signifi-
cant between the two sh-oligonucleotides and in more than
one experiment to reduce false positives or artifacts. We found
that PAFAH1B3 knockdown raises the levels of several lipid
species including phosphatidylcholines (PCs), lysophosphatidyl
choline (LPC), PEs, lysophosphatidyl ethanolamines (LPEs),
phosphatidic acids (PAs), PSs, phosphatidyl glycerol (PGs),
SMs, ceramide, sphingosine, triacylglycerols, and monoalkyl-
glycerols, as well as ether lipid counterparts (designated as
‘‘e’’ after lipid nomenclature; Figure 4C; Table S2). We
screened the lipids that contain potential hydrolyzable bonds
against purified PAFAH1B3, but none of these lipids were
direct substrates of PAFAH1B3 and were not turned over
(Figure S3). Thus, we interpret these changes to be indirect
alterations in lipid metabolism stemming from PAFAH1B3
inactivation.
Interestingly, several of the lipids that were elevated upon
PAFAH1B3 knockdown have been shown to possess antitu-
morigenic or proapoptotic effects. For example, ceramide
levels are elevated upon PAFAH1B3 knockdown and ceramide
is a well-established proapoptotic lipid (Morad and Cabot,
2013). The metabolites involved in ceramide biosynthesis,
including phosphatidylcholine (PC) and sphingomyelin, also
show heightened levels upon PAFAH1B3 knockdown. PS has
been shown to be elevated in cancer cells undergoing
apoptosis after chemotherapy or radiation treatment and is
involved in immune recognition and tumor clearance (Chao
et al., 2012). C16:0/C18:1 PC has been shown to act as a
PPARa agonist, and PPARa agonists have been shown to
have antitumorigenic and antiangiogenic properties (Chakra-
varthy et al., 2009; Huang et al., 2013; Liang et al., 2013; Pozzi
and Capdevila, 2008). Consistent with this premise, we found
that the PPARa agonist fenofibrate impaired cancer cell sur-
vival and proliferation in 231MFP cells and the PPARa antago-
nist GW6471 rescued the proliferative and survival defects of
PAFAH1B3 knockdown (Figure S3). Interestingly, we also found
that the elevated C16:0 LPC and C16:0/C18:1 PS also stimu-
lated PPARa activity (Figure S3).
Whereas our metabolomic data still did not reveal the direct
substrate of PAFAH1B3, our results indicate that PAFAH1B3
inactivation leads to a metabolomic signature that is enriched
in tumor-suppressing signaling lipids that may be in part831–840, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 835
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Figure 3. PAFAH1B2 and PAFAH1B3 Are Critical Metabolic Enzymes in Maintaining Breast Cancer Pathogenicity
(A) We stably knocked down the expression of PAFAH1B2 and PAFAH1B3 in the triple-negative aggressive 231MFP breast cancer cells with two independent
shRNA oligonucleotides by >80% as confirmed by qPCR.
(B–E) PAFAH1B2 and PAFAH1B3 knockdown impairs proliferation (B), serum-free cell survival (C), migration (D), and invasion (E).
(F) PAFAH1B2 and PAFAH1B3 knockdown also impairs tumor xenograft growth in immune-deficient SCID mice.
(G) Expression of PAFAH1B2 and PAFAH1B3 in normal mammary tissue and primary human breast tumors assessed by qPCR.
(H) Recurrence-free survival stratified by high versus low PAFAH1B3 expression in breast cancer patients overall and by lymph-node-negative/positive patients
and grade 1–3 breast cancer patients. These data are derived from the online resource known as the Kaplan-Meier Plotter (http://www.kmplot.com; Gyo¨rffy et al.,
2010). Data are presented as mean ± SEM; n = 4–8/group for (A–F), 7–41 patients/group for (G), and 306–3,455 patients for (H) as indicated. Significance is
presented as *p < 0.05 compared to normal tissue in (A) and compared to shControl 231MFP cells for (B)–(G). p values for (H) are indicated on the figure itself.
Protein expression data of PAFAH1B2 and PAFAH1B3 knockdown cells, a recapitulation of tumor growth deficits in shPAFAH1B3 cells, and PAFAH1B3
overexpression studies are shown in Figure S2.
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Figure 4. Metabolomic Profiling of PAFAH1B3 Knockdown Cells Reveals Elevations in Antitumorigenic Lipids
(A) Volcano plot showing all significantly altered metabolites from untargeted and targeted lipidomic profiling in shPAFAH1B3 knockdown 231MFP cancer cells.
The red and blue points correspond to elevated and reducedmetabolites, respectively. The points to the left of the dotted line are ions detected, but not changing,
upon PAFAH1B3 knockdown, whereas points to the right of the line are metabolites that are significantly changing (p < 0.05 compared to shControl cells).
(B) Heatmap showing representative metabolites identified through targeted SRM-based lipidomic analysis. Dark blue corresponds to highest levels, and white
corresponds to lowest levels. Metabolites highlighted in red are significantly changed (p < 0.05) in both shPAFAH1B3 lines and repeated in at least two inde-
pendent experiments.
(C) Bar graph showing relative levels of metabolites that are significantly altered in PAFAH1B3 knockdown cells normalized to shControl cells.
(D) Our results show that PAFAH1B3 inactivation leads to a metabolomic signature enriched in heightened levels of tumor-suppressing lipids such as ceramides
and PPARa ligands (e.g., PC, PS, and LPC). We postulate that this lipidomic signature contributes to reduced cancer pathogenicity upon PAFAH1B3 knockdown
in breast cancer cells. Data are presented as mean ± SEM; n = 5–6/group. Significance is presented as *p < 0.05 compared to shControl 231MFP breast cancer
cells. Detailed metabolomic data are shown in Table S2. PAF levels and PAFAH hydrolytic activity, lipid hydrolytic activities against PAFAH1B3, and studies
testing the role of PPARa in PAFAH1B3 effects upon cancer are shown in Figure S3.
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ogenicity and tumorigenicity.
Conclusions
Here, we have usedmultiple platforms, including protein expres-
sion profiling, ABPP, andmetabolomics, to broadly profile dysre-
gulated metabolism in a breast cancer progression model thatChemistry & Biology 21,incorporates cellular transformation through HRAS and EMT,
CSC-like features, and malignant progression through the
constitutive activation of TAZ. In addition to identifying several
canonical metabolic pathways, such as glycolysis, glycogen,
and lipogenic metabolism, which have already been shown to
be metabolic drivers of cancer, we have discovered PAFAH1B3
as an important metabolic enzyme that is important in driving831–840, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 837
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PAFAH1B3 in Breast Canceraggressive and tumorigenic features of breast cancer. Metabo-
lomic profiling reveals that PAFAH1B3 controls cancer cell path-
ogenicity through regulating an optimal landscape of signaling
lipids that may impair cancer aggressiveness.
Whereas PAFAH1B3 has been implicated as a PAF acetylhy-
drolase, our data indicate that PAF is likely not the endogenous
substrate of PAFAH1B3 in cancer cells. While we still do not
know the identification of this endogenous substrate, the
answer may lie in the altered metabolites that still remain unan-
notated from our metabolomic analyses of PAFAH1B3 inactiva-
tion. Identifying these unknown metabolites may further yield
mechanisms through which PAFAH1B3 exerts its pathogenic
effects in breast cancer cells. Alternatively, the endogenous
substrate may also not be a lipid, or even a metabolite, and
may operate on peptides, proteins, or protein posttranslational
modifications. Thus, it would be of future interest to further
investigate the direct substrates of PAFAH1B3 and how these
substrates lead to the lipidomic changes that we observe in
this study.
While we show that PAFAH1B2 and 1B3 knockdown lead to
impairments in cellular proliferation, survival, migration, and
invasiveness, the motility and invasiveness deficits may in
part be due to the proliferative and survival deficits. Thus, it
may be interesting to pursue those metabolic enzyme targets,
such as SIAE or NANS, that do not show proliferative deficits
but confer migratory impairments, because these targets may
regulate invasiveness of the cancer cells. It will also be of future
interest to investigate the roles of the other pathways and
enzymes that are under the control of HRAS, TAZ, or HRAS
and TAZ.
Overall, our results show many metabolic enzymes and
biochemical pathways that are dysregulated during cellular
transformation and also under malignant progression. Although
we focused on PAFAH1B3 in this study due to the striking phe-
notypes observed, many of the other targets may represent
unique metabolic nodes that influence various aspects of can-
cer pathogenicity. In this study, we have also identified multiple
metabolic genes, activities, metabolites, and pathways that are
regulated by the Hippo-signaling pathway. Previous studies
have shown that the Hippo transducer pathway controls a
diverse transcriptional network that drives EMT, cancer stem-
like properties, proliferation, survival, motility, invasiveness,
metastasis, and transformation (Cordenonsi et al., 2011; Lamar
et al., 2012). Here, we show that the Hippo transducers YAP
and TAZ collectively regulate the expression and activities of
critical metabolic drivers of cancer pathogenicity. We show
that the Hippo transducer pathway strongly regulates glycolytic
enzymes and glycolytic metabolism alone or in conjunction with
HRAS, thus likely contributing to the glycolytic addiction or the
‘‘Warburg effect’’ that subserves cancer pathogenicity. We also
show here that the Hippo transducer pathway regulates many
other metabolic enzymes that have been linked to controlling
pathogenic features of cancer, including SDHA, FASN, MGLL,
FAP, PPME1, and neutral cholesteryl ester hydrolase 1
(NCEH1, also known as KIAA1363). SDHA loss-of-function
mutations, through accumulation of succinate and inhibition
of alpha-ketoglutarate-dependent oxygenases, have been
shown to enhance glycolysis, angiogenesis, and epigenetic
alterations that fuel cancer (Yang et al., 2013). Both FASN838 Chemistry & Biology 21, 831–840, July 17, 2014 ª2014 Elsevier Land MGLL have been previously shown to be critical in cancer
pathogenicity through controlling lipogenic and lipolytic path-
ways in cancer cells, respectively (Menendez and Lupu, 2007;
Nomura et al., 2010b, 2011). FAP, a serine protease selectively
expressed on tumor-associated fibroblasts and pericytes, has
been shown to drive tumor stromagenesis and tumor growth
(Santos et al., 2009). PPME1, a demethylase and inhibitor of
protein phosphatase 2A, helps to promote protumorigenic
phosphorylation signaling cascades (Bachovchin et al., 2011;
Puustinen et al., 2009). Interestingly, NCEH1 is upregulated
only upon induction of HRAS and TAZ S89A, indicating that
both oncogenic stimuli are required for elevating KIAA1363
activity. This enzyme has been shown to drive cancer cell
migration and tumorigenesis through controlling ether lipid-
signaling pathways (Chang et al., 2011; Chiang et al., 2006).
Thus, we show that the Hippo transducer is a critical factor in
controlling the metabolic programming that drives the patho-
genic properties of cancer.
Our studies underscore the utility of multidimensional meta-
bolic profiling efforts in uncovering unique metabolic nodes in
cancer, and we put forth PAFAH1B3 as a potential therapeutic
target for the treatment of aggressive breast cancers.
SIGNIFICANCE
Whereas many recent studies have revealed key metabolic
pathways that underlie cellular transformation, the meta-
bolic drivers of cancer malignancy are less well understood.
Here, we have performed a massively parallel metabolic
profiling study to identify metabolic drivers underlying a
breast cancer progression model that incorporates both
cellular transformation by RAS and malignant progression
by the Hippo transducer TAZ.We have discoveredmetabolic
pathways including glycolytic, lipogenic, and lipolytic pro-
cesses that have been previously linked to cancer patho-
genicity that are coordinately regulated through both the
RAS and Hippo pathways. Most notably, we have uncovered
an important metabolic enzyme PAFAH1B3 as a critical
driver of breast cancer pathogenicity through controlling
tumor-suppressing signaling lipids. Overall, we show the
utility of multidimensional metabolic profiling strategies in
assembling a metabolic map of breast cancer progression
and put forth PAFAH1B3 as a potential enzyme target for
breast cancer therapy.
EXPERIMENTAL PROCEDURES
Cell Lines
The MCF10A, MII, MII TAZ S89A, and MIV lines were provided by Professor
Stefano Piccolo at the University of Padua (Cordenonsi et al., 2011). The
231MFP cells were generated from explanted xenograft tumors of MDA-
MB-231 cells, as described previously (Jessani et al., 2004).
Cell Culture Conditions
Human embryonic kidney 293T cells were cultured in Dulbecco’s modified
Eagles’ medium (DMEM) media containing 10% fetal bovine serum (FBS)
and maintained at 37C with 5% CO2. 231MFP cells were cultured in L15
media containing 10% FBS and glutamine and were maintained at 37C in
0% CO2. MCF10A and MCF10A-derived lines were cultured in DMEM/F12K
media containing 5% (vol/vol) horse serum, 1% (vol/vol) penicillin-strepto-
mycin-glutamine, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin,td All rights reserved
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PAFAH1B3 in Breast Cancer10 ng/ml insulin, and 500 ng/ml hydrocortisone and maintained at 37C at 5%
(wt/vol) CO2 as described previously (Cordenonsi et al., 2011).
qPCR
qPCR was performed using the manufacturer’s protocol for Fischer Maxima
SYBRgreen, with 10 mM primer concentrations. Primer sequences were
derived from Primer Bank (Spandidos et al., 2010).
Cancer Phenotype Studies
Migration, invasion, cell proliferation, and survival studies were performed as
described previously (Nomura et al., 2010b).
Shotgun Proteomic Profiling of Cancer Cells
Proteins (100 mg) were TCA precipitated in 20% TCA at 80C overnight and
then centrifuged at 10,000 3 g at 4C for 10 min to pellet protein. The protein
pellets were washed three timeswith 8Murea in PBS. After solubilization, 30 ml
of 0.2% Protease Max Surfactant (Promega) was added and the resulting
mixture was vortexed followed by the addition of 40 ml of 100 mM ammonium
bicarbonate and 10 mM tris(2-carboxyethyl)phosphine. After 30 min, 12.5 mM
iodoacetamide was added and allowed to react for 30 min in the dark before
adding 120 ml PBS and 1.2 ml 1%ProteaseMax Surfactant (Promega). The pro-
tein solution was vortexed and 0.5 mg/ml Sequencing Grade Trypsin (Promega)
was added and allowed to react overnight at 37C. The peptide solution was
subjected to a 30 min 10,0003 g spin before the supernatant was transferred
to a new tube and loaded onto a biphasic (strong cation exchange/reverse
phase) capillary column and analyzed by 2D liquid chromatography in combi-
nation with tandem mass spectrometry on a nanospray Thermo LTQ-XL MS/
MS. The data were analyzed using the Integrated Proteomics Pipeline (IP2)
as described previously (Nomura et al., 2010b).
Activity-Based Protein Profiling of Cancer Cells
ABPP-MudPIT analysis was performed using previously established proce-
dures (Nomura et al., 2010b). Briefly, 1 mg protein was labeled with 5 mM fluo-
rophosphonate-biotin in 1 ml PBS for 1 hr at room temperature, solubilized in
1%Triton X-100 for 1 hr, denatured, and labeled enzymeswere enriched using
avidin beads, reduced and alkylated, and trypsinized. Tryptic peptides were
analyzed on a Thermo LTQ-XL MS/MS as described previously (Nomura
et al., 2010b).
Metabolomic Profiling of Cancer Cells
Metabolite measurements were conducted using modified versions of previ-
ous procedures (Kopp et al., 2010; Nomura et al., 2010b). Details are
described in Supplemental Experimental Procedures.
RNA Interference of Enzymes
For siRNA knockdown, cells were treated with ON-TARGETplus SMARTpool
siRNA (Thermo) per the manufacturer’s protocol. Two hundred thousand cells
were treated with 50 nM siRNA using DharmaFECT 1 Transfection Reagent.
Assays were performed after 48 hr of treatment. We confirmed knockdown
by qPCR.
We used short-hairpin RNA (shRNA) using two independent silencing oligo-
nucleotides to knockdown the expression of PAFAH1B2 and PAFAH1B3 using
previously described procedures (Nomura et al., 2010b). Details are described
in Supplemental Experimental Procedures.
Overexpression of PAFAH1B2 or PAFAH1B3 in MCF10A Cells
Stable PAFAH1B3 overexpression was achieved by subcloning the
PAFAH1B3 gene from fully sequenced human cDNA (Thermo Scientific) into
the pLenti CMV puro DEST vector (Addgene 17452) using the gateway cloning
system (Life Technologies). The PAFAH1B3 Ser 47 Alamutant wasmade using
Quick-Change Mutagenesis to mutate base 139 (Stratagene).
Breast Tumor Array qPCR
Breast cancer tumor array 1was purchased fromOriGene, and qPCRwas per-
formed on the array using the protocol described above.Chemistry & Biology 21,Tumor Xenograft Studies
All experimental protocols used were approved by the Animal Care and Use
Committee of the University of California, Berkeley. Human tumor xenografts
were established by transplanting cancer cells ectopically into the flank of
C.B17 severe combined immunodeficiency (SCID) mice (Taconic Farms) as
described previously (Nomura et al., 2010b). Briefly, cells were washed two
times with PBS, trypsinized, and harvested in serum-containing medium.
Next, the harvested cells were washed two times with serum-free medium
and resuspended at a concentration of 2.0 3 104 cells/ml and 100 ml was in-
jected. Growth of the tumors was measured every 3–6 days with calipers.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2014.05.008.
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